Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis

被引:49
作者
Rencz, F. [1 ,2 ]
Gulacsi, L. [1 ]
Pentek, M. [1 ]
Poor, A. K. [3 ]
Sardy, M. [3 ]
Hollo, P. [3 ]
Szegedi, A. [4 ,5 ]
Remenyik, E. [4 ]
Brodszky, V. [1 ]
机构
[1] Corvinus Univ Budapest, Dept Hlth Econ, Fovam Ter 8, H-1093 Budapest, Hungary
[2] Hungarian Acad Sci, Premium Postdoctoral Res Programme, H-1051 Budapest, Hungary
[3] Semmelweis Univ, Fac Med, Dept Dermatol Venereol & Dermatooncol, Maria U 41, H-1085 Budapest, Hungary
[4] Univ Debrecen, Fac Med, Dept Dermatol, Nagyerdei Krt 98, H-4032 Debrecen, Hungary
[5] Univ Debrecen, Fac Med, Dept Dermatol Allergol, Nagyerdei Krt 98, H-4032 Debrecen, Hungary
关键词
OF-LIFE; BIOLOGICAL THERAPIES; OUTCOME MEASURES; HAND ECZEMA; DLQI; MODERATE; INSTRUMENTS; RELIABILITY; VALIDITY; DECISION;
D O I
10.1111/bjd.16927
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background 'Not relevant' responses (NRRs) on the Dermatology Life Quality Index (DLQI) may occur in up to 40% of patients with psoriasis. As these responses are scored as the item of the questionnaire having no impact on the patients' lives at all, it is more difficult for these patients to fulfil the DLQI > 10 criterion required by clinical guidelines to become candidates for systemic treatment including biologics. Objectives Methods We propose a new scoring system for the DLQI that corrects for the bias in the NRR option and test its construct validity in a sample of patients with psoriasis. Data from 242 patients (104 of whom marked at least one NRR) from two earlier cross-sectional surveys were reanalysed. For each patient, the DLQI score was calculated in two ways: (i) according to the original scoring and (ii) by applying a new scoring formula (DLQI-R) that adjusts the total score for the number of NRRs. The construct validity of the DLQI-R was tested against the Psoriasis Area and Severity Index (PASI) and EQ-5D-3L. Results Conclusions The mean DLQI and DLQI-R scores were 9 center dot 99 +/- 7 center dot 52 and 11 center dot 0 +/- 8 center dot 02, respectively. The DLQI-R allowed eight more patients (3 center dot 3%) to achieve the 'PASI > 10 and DLQI > 10' threshold. The results were robust when limiting the maximum number of NRRs allowed to two or three. Compared with the DLQI, DLQI-R correlated slightly better with PASI (r(s) = 0 center dot 59 vs. 0 center dot 57) and EQ-5D-3L index scores (r(s) = -0 center dot 58 vs. -0 center dot 54). The DLQI-R seems to be a valid scoring system for avoiding the bias in the NRR option and can help to improve patients' access to biologics.
引用
收藏
页码:1102 / 1108
页数:7
相关论文
共 48 条
[1]   A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis [J].
Ali, F. M. ;
Cueva, A. C. ;
Vyas, J. ;
Atwan, A. A. ;
Salek, M. S. ;
Finlay, A. Y. ;
Piguet, V. .
BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) :577-593
[2]  
[Anonymous], 2002, Br J Dermatol
[3]  
Badia X, 1999, BRIT J DERMATOL, V141, P698
[4]   The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results [J].
Basra, M. K. A. ;
Fenech, R. ;
Gatt, R. M. ;
Salek, M. S. ;
Finlay, A. Y. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (05) :997-1035
[5]   Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatogy Life Quality Index (DLQI): Further Data [J].
Basra, M. K. A. ;
Salek, M. S. ;
Camilleri, L. ;
Sturkey, R. ;
Finlay, A. Y. .
DERMATOLOGY, 2015, 230 (01) :27-33
[6]   Financial deficits in the health services of the UK and Hungary [J].
Boncz, Imre ;
Sebestyen, Andor .
LANCET, 2006, 368 (9539) :917-918
[7]   What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature [J].
Bronsard, V. ;
Paul, C. ;
Prey, S. ;
Puzenat, E. ;
Gourraud, P-A ;
Aractingi, S. ;
Aubin, F. ;
Bagot, M. ;
Cribier, B. ;
Joly, P. ;
Jullien, D. ;
Le Maitre, M. ;
Richard-Lallemand, M-A ;
Ortonne, J-P .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 :17-22
[8]   EuroQol: The current state of play [J].
Brooks, R .
HEALTH POLICY, 1996, 37 (01) :53-72
[9]   Modeling valuations for EuroQol health states [J].
Dolan, P .
MEDICAL CARE, 1997, 35 (11) :1095-1108
[10]   Psoriasis registries worldwide: systematic overview on registry publications [J].
Eissing, L. ;
Rustenbach, S. J. ;
Krensel, M. ;
Zander, N. ;
Spehr, C. ;
Radtke, M. A. ;
Naldi, L. ;
Augustin, M. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (07) :1100-1106